ArticleLancet regional health. Americas2024
Impact of Xpert MTB/RIF implementation in tuberculosis case detection and control in Brazil: a nationwide intervention time-series analysis (2011-2022).
Article in Lancet regional health. Americas, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Novel RT‒qPCR-based blood signatures for the diagnosis of pulmonary tuberculosis.Scientific reports · 2026Article
- Spatiotemporal Patterns and Socioeconomic Determinants of Pulmonary Tuberculosis in Piauí, Northeast Brazil, 2001-2024.Tropical medicine & international health : TM & IH · 2026Article
- Spatio-temporal modeling of tuberculosis among Brazil's elderly: a 20-year ecological and population-based study.BMC infectious diseases · 2026Article
- Global, Regional, and National Burden of Tuberculosis Among Children: A Population-Based Study.Tropical medicine and infectious disease · 2026Article
- Factors associated with unsuccessful treatment outcomes among drug-resistant tuberculosis patients in Loreto, Peru, 2015-2023: A retrospective cohort study.PLOS global public health · 2026Article
- Projecting tuberculosis control progress in metropolitan and non-metropolitan areas of Brazil, 2001-2035: a Bayesian age-period-cohort analysis.Infectious diseases of poverty · 2025Article
- Temporal Trends in Tuberculosis Incidence in the 1st Health Region of Alagoas, Brazil (2001-2022).International journal of environmental research and public health · 2025Article
- Fifteen years of tuberculosis and HIV diagnostic services in Brazil: disruption, regional disparities, and recovery before, during, and after the COVID-19 pandemic.IJID regions · 2025Article
- From Patterns to Projections: A Spatiotemporal Distribution of Drug-Resistant Tuberculosis in Paraná, Brazil (2012-2023).Pathogens (Basel, Switzerland) · 2025Article
- Tuberculosis and the Research Workforce Renewal Crisis in Brazil: How Can We Prevent a Future Without New Researchers?Revista da Sociedade Brasileira de Medicina Tropical · 2025Review
- A Genome-Focused Investigation Reveals the Emergence of aMicroorganisms · 2024Article
- The performance of Xpert MTB/RIF and MTBDRplus within a Programmatic setting at TB Laboratory in Rio de Janeiro, Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Since 2014, Brazil has gradually implemented the Xpert MTB/RIF (Xpert) test to enhance early tuberculosis (TB) and drug-resistant (DR-TB) detection and control, yet its nationwide impact remains underexplored. Our study conducts an intervention time-series analysis (ITSA) to evaluate how the Xpert's implementation has improved TB and DR-TB detection nationwide. Methods: 1,061,776 cases from Brazil's National TB Registry (2011-2022) were reviewed and ITSA (2011-2019) was used to gauge the impact of the Xpert's adoption on TB and DR-TB notification. Granger Causality and dynamic regression modelling determined if incorporating Xpert testing as an external regressor enhanced forecasting accuracy for Brazil's future TB trends. Findings: Xpert implementation resulted in a 9.7% increase in TB notification and substantial improvements in DR-TB (63.6%) and drug-susceptible TB (92.1%) detection compared to expected notifications if it had not been implemented. Xpert testing counts also presented a time-dependent relationship with DR-TB detection post-implementation, and improved predictions in forecasting models, which depicted a potential increase in TB and DR-TB detection in the next six years. Interpretation: This study underscores the critical role of Xpert's adoption in boosting TB and DR-TB detection in Brazil, reinforcing the case for its widespread use in disease control. Improvements in prediction accuracy resulting from integrating Xpert data are crucial for allocating resources and reducing the incidence of TB. By acknowledging Xpert's role in both disease control and improving predictions, we advocate for its expanded use and further research into advanced molecular diagnostics for effective TB and DR-TB control. Funding: FIOCRUZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.